Rage targeting therapeutic exosome for drug delivery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Gyeungyun | - |
dc.contributor.author | Lee, Minhyung | - |
dc.date.accessioned | 2022-07-10T01:01:53Z | - |
dc.date.available | 2022-07-10T01:01:53Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 1526-7547 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/148094 | - |
dc.description.abstract | Statement of Purpose: Among extracellular vesicles (EVs), membrane-derived vesicles that secreted by various types of cells for cell-cell signaling, exosome is the smallest subtype with size of 30 to 100 nm in diameter. Since exosomes were small and native to the animals, they have several advantages as drug delivery carrier. There have been several trials to decorated exosome with ligands by production of a fusion protein of a ligand and an exosome-membrane protein, Lamp2b.(1, 2) As a potential therapeutic target, RAGE is a pattern-recognition receptor that binds to endogenous damage associated molecular patterns (DAMP); signal molecules that initiate a noninfectious inflammatory response. It was previously reported that RAGE-binding peptide (RBP) derived from high-mobility group box-1 (HMGB1) suppress inflammatory response by working as an antagonist of DAMP.(3) We hypothesized that RBP-decorated exosome could deliver drug specifically to RAGE-overexpressed cells. Thus, in this research, RAGE-targeting exosome was produced by expression of a fusion protein of RBP and Lamp2b. To evaluate targeting drug delivery efficiency of RBP-decorated exosome (RBP-exo), curcumin, a natural polyphenolic drug, was loaded into exosomes and delivered to inflammatory cells. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Society for Biomaterials | - |
dc.title | Rage targeting therapeutic exosome for drug delivery | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Minhyung | - |
dc.identifier.scopusid | 2-s2.0-85065402388 | - |
dc.identifier.bibliographicCitation | Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium, v.40, pp.544 - 544 | - |
dc.relation.isPartOf | Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium | - |
dc.citation.title | Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium | - |
dc.citation.volume | 40 | - |
dc.citation.startPage | 544 | - |
dc.citation.endPage | 544 | - |
dc.type.rims | ART | - |
dc.type.docType | Conference Paper | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | Biological membranes | - |
dc.subject.keywordPlus | Cell signaling | - |
dc.subject.keywordPlus | Cells | - |
dc.subject.keywordPlus | Controlled drug delivery | - |
dc.subject.keywordPlus | Cytology | - |
dc.subject.keywordPlus | Ligands | - |
dc.subject.keywordPlus | Pattern recognition | - |
dc.subject.keywordPlus | Proteins | - |
dc.subject.keywordPlus | Cell-cell signaling | - |
dc.subject.keywordPlus | Drug delivery carrier | - |
dc.subject.keywordPlus | High-mobility groups | - |
dc.subject.keywordPlus | Inflammatory cells | - |
dc.subject.keywordPlus | Inflammatory response | - |
dc.subject.keywordPlus | Pattern recognition receptors | - |
dc.subject.keywordPlus | Targeting drug deliveries | - |
dc.subject.keywordPlus | Therapeutic targets | - |
dc.subject.keywordPlus | Targeted drug delivery | - |
dc.identifier.url | https://2019.biomaterials.org/sites/default/files/abstracts/714.pdf | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.